Slowing Parkinson's disease progression - Recent dopamine agonist trials

被引：120
|
作者：
Ahlskog, JE [1 ]
机构：
[1] Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA
来源：
NEUROLOGY | 2003年 / 60卷 / 03期
关键词：
D O I：
10.1212/01.WNL.0000044047.58984.2F
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
In recent clinical trials, chronic treatment of patients With PD with pramipexole or ropinirole was associated with a slower decline of imaged striatal dopaminergic signal, compared to levodopa monotherapy. Although this could reflect slowed progression of PD, equally plausible is a pharmacologic effect on proteins that interact with the imaging radioligands. To date, there is no compelling evidence favoring dopamine agonists over levodopa; either is an appropriate choice for initial treatment of PD.
引用
收藏
页码：381 / 389
页数：9
相关论文
共 50 条
  • [41] Recent important trials of pharmacotherapy in Parkinson's disease
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 1025 - 1028
  • [42] An economic model of Parkinson's disease: Implications for slowing progression in the United States
    Johnson, Scott J.
    Diener, Melissa D.
    Kaltenboeck, Anna
    Birnbaum, Howard G.
    Siderowf, Andrew D.
    MOVEMENT DISORDERS, 2013, 28 (03) : 319 - 326
  • [43] Imaging of dopamine transporters: Biomarker for progression in Parkinson's disease
    Innis, RB
    Seibyl, J
    Marek, K
    CNS DRUG REVIEWS, 2000, 6 : 33 - 33
  • [44] Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis
    Conrado, Daniela J.
    Nicholas, Timothy
    Tsai, Kuenhi
    Macha, Sreeraj
    Sinha, Vikram
    Stone, Julie
    Corrigan, Brian
    Bani, Massimo
    Muglia, Pierandrea
    Watson, Ian A.
    Kern, Volker D.
    Sheveleva, Elena
    Marek, Kenneth
    Stephenson, Diane T.
    Romero, Klaus
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2018, 11 (01): : 63 - 70
  • [45] Pharmacokinetic Optimisation of Dopamine Receptor Agonist Therapy for Parkinson’s Disease
    Manuela Contin
    Roberto Riva
    Fiorenzo Albani
    Agostino Baruzzi
    CNS Drugs, 2000, 14 : 439 - 455
  • [46] Dopamine agonist-based strategies in the treatment of Parkinson’s disease
    Angelo Antonini
    Paolo Barone
    Neurological Sciences, 2008, 29 : 371 - 374
  • [47] Initial therapy in Parkinson's disease should begin with a dopamine agonist: NO
    Weiner, WJ
    MOVEMENT DISORDERS, 2004, 19 : S14 - S14
  • [48] Causes and factors related to dopamine agonist withdrawal in Parkinson's disease
    Suarez Castro, Ester
    Santos-Garcia, Diego
    de Deus Fonticoba, Teresa
    Exposito Ruiz, Irene
    Tunas Gesto, Cintia
    Macias Arribi, Mercedes
    BRAIN AND BEHAVIOR, 2016, 6 (07):
  • [49] Introduction: pramipexole: a novel dopamine agonist for the treatment of Parkinson's disease
    de Yebenes, JG
    EUROPEAN JOURNAL OF NEUROLOGY, 2000, 7 : 1 - 2
  • [50] TRANSDERMAL DOPAMINE AGONIST AMELIORATES GASTRIC EMPTYING IN PARKINSON'S DISEASE
    Sakakibara, R.
    Doi, H.
    Shiina, S.
    Tateno, F.
    Tateno, H.
    Kishi, M.
    Tsuyusaki, Y.
    Aiba, Y.
    Yamamoto, T.
    Yamanishi, T.
    Uchiyama, T.
    Shibata, C.
    NEUROUROLOGY AND URODYNAMICS, 2015, 34 : S329 - S330
12345